Name: Cerebrolysin
Brand: Peptific
SKU: CEREBROLYSIN-STANDARD

Cerebrolysin is a standardized porcine brain peptide hydrolysate approved in 50+ countries for stroke, TBI, and Alzheimer's — engaging BDNF, GDNF, NGF, and VEGF receptor pathways via its complex peptide mixture.

Nootropic Peptides

Cerebrolysin

Cerebrolysin is a standardized preparation of neurotrophic peptide fragments derived from controlled enzymatic hydrolysis of porcine brain protein. Unlike single-molecule research peptides, it is a complex biological mixture: approximately 25% low-molecular-weight peptides (molecular weight <10,000 Da) and 75% amino acids, with the peptide fraction containing compounds with functional similarity to endogenous neurotrophic factors at the receptor level. The regulatory footprint is exceptional. Cerebrolysin is approved as a pharmaceutical in more than 50 countries — including approval across EU member states, China, South Korea, Russia, and multiple other regulatory jurisdictions — for stroke, traumatic brain injury (TBI), and Alzheimer's disease. Multiple regulatory agencies have independently reviewed and approved clinical trial data for these neurological indications, providing a pharmacovigilance and efficacy dataset that spans decades of post-marketing clinical use. The proposed mechanism distinguishes it from single neurotrophic compounds: Cerebrolysin's peptide fraction activates BDNF TrkB and p75NTR receptors, GDNF signaling pathways, NGF-like activity, and VEGF-mediated neuroprotection — engaging the full neurotrophic factor receptor network rather than a single target. Published research has documented reduced neuronal apoptosis, enhanced synaptic plasticity, improved mitochondrial function in neurons, and anti-amyloid effects in Alzheimer's model systems. For researchers studying multimodal neuroregeneration, acute neuroprotection, Alzheimer's disease mechanisms, TBI recovery biology, or the neurotrophic factor axis across aging and neurological disease, Cerebrolysin provides both an extensive clinical evidence base and a mechanistically complex tool for studying multi-neurotrophic-pathway activation. This listing is for laboratory and preclinical research purposes only. Not for human or veterinary use.

Product Information

Shipping & Returns

Research reference only

This product is listed for research reference and is not currently available for ordering. See live alternatives below or contact the team.

Notify me when available

Currently unavailable

This product is listed for research reference. It is not currently available for ordering. Live alternatives from the same research category are shown below.

Product definition

What is Cerebrolysin?

Cerebrolysin (EVER Neuro Pharma, Austria) is produced by controlled enzymatic hydrolysis of porcine brain protein, yielding a mixture of approximately 85 amino acids and short peptide chains with molecular weights predominantly below 10,000 Da. The mixture is standardized to defined nitrogen content and peptide composition per batch. The active neurotrophic fraction consists of peptides with structural and functional similarity to BDNF, GDNF, NGF, and VEGF fragments — which appear to activate their respective receptor systems without being the intact growth factors themselves. The clinical approval database spans three major neurological indications across multiple regulatory jurisdictions: acute ischemic stroke (IV administration in the acute and subacute phases), traumatic brain injury (IV administration for recovery support), and Alzheimer's disease (cognitive stabilization, documented in multiple RCTs). The Cochrane Collaboration has produced systematic reviews of the Cerebrolysin stroke and dementia clinical trial literature, providing independent meta-analytic assessment of the available evidence. In preclinical research contexts, Cerebrolysin is used as a multi-neurotrophic-factor reference preparation for investigating how simultaneous activation of multiple neurotrophic receptor systems affects neuronal survival, plasticity, and recovery — research questions that cannot be addressed with single neurotrophic factor compounds.

Research context

How is Cerebrolysin described in the research literature?

Cerebrolysin's peptide fraction activates BDNF TrkB/p75NTR, GDNF, NGF, and VEGF signaling pathways simultaneously — a multi-neurotrophic-factor receptor activation profile that distinguishes it from single-molecule neuropeptides. Approved in 50+ countries for stroke, TBI, and Alzheimer's disease; Cochrane reviews have analyzed its clinical trial database across these indications.

Compound profile

Key facts about Cerebrolysin

Class: Standardized porcine brain peptide hydrolysate
Composition: ~25% low-MW peptides (<10 kDa), ~75% amino acids
Active mechanism: BDNF TrkB/p75NTR, GDNF, NGF, VEGF pathway activation
Clinical status: Approved in 50+ countries for stroke, TBI, Alzheimer's
Formulation: IV solution (sterile, ready for research use)
Evidence reviews: Cochrane systematic reviews published for stroke and dementia indications
Research category: Neuroprotection, neuroregeneration, Alzheimer's, TBI, neurotrophic factor biology
Storage: 2–8°C, protected from freezing and light. Do not freeze.

Research areas

What research areas is Cerebrolysin associated with?

Approved in 50+ countries for stroke, TBI, and Alzheimer's — broadest regulatory approval base of any neurotrophic research compound
Activates BDNF, GDNF, NGF, and VEGF receptor pathways simultaneously — multi-neurotrophic-factor profile in single preparation
Cochrane systematic reviews of stroke and Alzheimer's clinical trial data — independent evidence analysis available
Decades of post-marketing clinical pharmacovigilance across multiple national regulatory systems
IV formulation for direct CNS exposure research — relevant for acute neuroprotection and neuroregeneration protocols
Unique research tool for studying multi-pathway neurotrophic receptor co-activation vs. single-factor compounds

Research audience

Who researches Cerebrolysin?

Cerebrolysin is used by researchers in neuroprotection, neuroregeneration, Alzheimer's disease biology, TBI recovery mechanisms, stroke pharmacology, and the neurotrophic factor axis in aging and neurodegeneration. It is the reference multi-neurotrophic preparation for investigators studying the combined neurotrophic factor receptor network rather than isolated single-factor pharmacology.

Preclinical research overview

What does the preclinical literature say about Cerebrolysin?

Cerebrolysin was developed in Austria in the 1940s-50s from the rationale that brain peptide hydrolysates might provide the neurotrophic signals that injured or aging neurons are deprived of. This concept predates the molecular characterization of BDNF, NGF, GDNF, and related factors — the finding that Cerebrolysin's peptide fraction activates these specific receptor systems was characterized retrospectively as the individual neurotrophic factors were identified. The clinical database is the compound's most distinctive feature. Multiple prospective, randomized, controlled trials have been conducted across its three indications in European, Asian, and post-Soviet regulatory contexts. The Cochrane reviews found evidence of functional improvement in stroke patients compared to placebo, with a safety profile consistent with the long regulatory history. The Alzheimer's data showed cognitive stabilization effects in several trials, though effect sizes and methodological consistency are debated in the literature. In translational research, the mechanistic question Cerebrolysin enables is: what is the net effect of activating the full set of neurotrophic receptor systems simultaneously, and does this multi-receptor approach produce different (better or worse) neurological recovery than targeting individual factors? This is a research question that single neurotrophic compounds cannot address.

Common questions

Frequently asked about Cerebrolysin

How does Cerebrolysin's evidence compare to single neurotrophic peptides like BDNF?

Single neurotrophic factors (recombinant BDNF, GDNF) have well-characterized receptor pharmacology but significant challenges as research tools: CNS penetration is poor from systemic administration, and isolated receptor activation does not capture how the neurotrophic network normally operates. Cerebrolysin activates multiple neurotrophic pathways simultaneously — mimicking a complex endogenous context — with the additional advantage of 50+ country regulatory approval and decades of clinical pharmacovigilance. For researchers studying multi-pathway neuroprotection or brain recovery biology, Cerebrolysin's multi-receptor engagement is a research advantage over isolated single neurotrophic compounds.

Is Cerebrolysin's porcine origin a research concern?

Porcine brain protein hydrolysate has been used in pharmaceutical Cerebrolysin production for decades under standardized manufacturing conditions with documented pathogen elimination steps in the production process. The EU-approved pharmaceutical formulation meets the applicable biological safety requirements for the approved indications. Researchers working with the pharmaceutical formulation can reference the manufacturer's batch characterization and safety documentation.

What is the storage requirement for Cerebrolysin?

Cerebrolysin IV solution should be stored at 2–8°C and must not be frozen — freezing can destabilize the peptide mixture and alter the biological activity of the preparation. Protect from light. The IV formulation does not require reconstitution — it is supplied as a ready-to-use solution. Check lot-specific stability data for exact use-by dating.